AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method of polyubiqutinating a nucleophosmin comprising [of] reacting the nucleophosmin with BRCA1-BARD1.

2. (Currently amended) A method of stabilizing a nucleophosmin comprising ~~of polyubiqutination of~~ polyubiquitinating nucleophosmin.

3. (Original) The method of Claim 1 or 2, wherein polyubiquitination is carried out *in vitro* or *in vivo*.

4. (Currently amended) A method of inhibiting polyubiquitination of nucleophosmin comprising [of] phosphorylating BARD1 using CDK2-cyclin E or CDK2-cyclin A.

5. (Currently amended) A method of degrading and/or dissociating BRCA1-BARD1 comprising [of] phosphorylating BARD1 using CDK2-cyclin E and/or CDK2-cyclin A.

6. (Currently amended) A method of inactivating ubiquitin ligase activity of a BRCA1-BARD1 comprising [of] phosphorylating BARD1 using CDK2-cyclin E and/or CDK2-cyclin A.

7. (Currently amended) The method according to any one of Claims 4 to 6, wherein the phosphorylation sites of BARD1 are at least three sites selected from the group consisting of S148, S251, S288 and T299.

8. (Currently amended) The method according to any one of Claims 4 to 6, wherein the phosphorylation sites of BARD1 are S148, S288 and T299.

9. (Currently amended) The method according to any one of Claims 4 to 6, wherein the phosphorylation sites of BARD1 are S148, S251, S288 and T299.

10. (Currently amended) A method of transporting BRCA1 from a nucleus to cytoplasm ~~wherein~~ comprising co-expressing BRCA1 and CDK2-cyclin E and/or CDK2-cyclin A ~~are co-expressed~~.